Looking for volunteers
R.E.C.K vs Exparel in Robotic Nephrectomy
NCT07092566 · Wake Forest University Health Sciences · Updated 13 July 2026
- What is being tested
- Ropivacaine HCL; Exparel; Epinephrine; Clonidine HCL; Ketorolac
- For
- Renal Carcinoma; Nephrectomy / Methods; Pain Management
- Kind of study
- Tests a treatment or device on volunteers. Phase 3.
- Who can join
- Ages 18 years and older. About 170 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 14 Nov 2025, ends Oct 2027. Registered 30 July 2025.
- Results
- None posted yet.
In the researchers' words
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Sites
- Levine CancerCharlotte, North Carolina, United States